Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response | ||
| dc.conicet.organizacion | Albert Ludwigs University of Freiburg | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Istituto di Ricovero e Cura a Carattere Scientifico | |
| dc.conicet.organizacion | Istituto di Ricovero e Cura a Carattere Scientifico | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Istituto di Ricovero e Cura a Carattere Scientifico | |
| dc.conicet.organizacion | Universite de Lausanne | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.conicet.organizacion | Universitat Zurich | |
| dc.conicet.organizacion | Istituto di Ricovero e Cura a Carattere Scientifico | |
| dc.conicet.organizacion | Vita Salute Universidad San Raffaele | |
| dc.conicet.organizacion | German Cancer Research Center | |
| dc.conicet.organizacion | Universite de Fribourg (unifr) | |
| dc.contributor.author | Apostolova, Petya | |
| dc.contributor.author | Kreutmair, Stefanie | |
| dc.contributor.author | Toffalori, Cristina | |
| dc.contributor.author | Punta, Marco | |
| dc.contributor.author | Unger, Susanne | |
| dc.contributor.author | Burk, Ann Cathrin | |
| dc.contributor.author | Wehr, Claudia | |
| dc.contributor.author | Maas Bauer, Kristina | |
| dc.contributor.author | Melchinger, Wolfgang | |
| dc.contributor.author | Haring, Eileen | |
| dc.contributor.author | Höfflin, Rouven | |
| dc.contributor.author | Shoumariyeh, Khalid | |
| dc.contributor.author | Hupfer, Valerie | |
| dc.contributor.author | Lauer, Eliza Maria | |
| dc.contributor.author | Duquesne, Sandra | |
| dc.contributor.author | Lowinus, Theresa | |
| dc.contributor.author | Núñez, Nicolás | |
| dc.contributor.author | Alberti, Chiara | |
| dc.contributor.author | da Costa Pereira, Sara | |
| dc.contributor.author | Merten, Carla Helena | |
| dc.contributor.author | Power, Laura | |
| dc.contributor.author | Weiss, Matthias | |
| dc.contributor.author | Böke, Caroline | |
| dc.contributor.author | Pfeifer, Dietmar | |
| dc.contributor.author | Marks, Reinhard | |
| dc.contributor.author | Bertz, Hartmut | |
| dc.contributor.author | Wäsch, Ralph | |
| dc.contributor.author | Ihorst, Gabriele | |
| dc.contributor.author | Gentner, Bernhard | |
| dc.contributor.author | Duyster, Justus | |
| dc.contributor.author | Boerries, Melanie | |
| dc.contributor.author | Andrieux, Geoffroy | |
| dc.contributor.author | Finke, Juergen | |
| dc.contributor.author | Becher, Burkhard | |
| dc.contributor.author | Vago, Luca | |
| dc.contributor.author | Zeiser, Robert | |
| dc.date.issued | 2023-10 | |
| dc.description.abstract | Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1–7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+, HLA-DR+), low senescence (KLRG1−, CD57−) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT. | es |
| dc.description.fil | Fil: Apostolova, Petya. Albert Ludwigs University of Freiburg; Alemania. German Cancer Research Center; Alemania | |
| dc.description.fil | Fil: Kreutmair, Stefanie. Universitat Zurich; Suiza. German Cancer Research Center; Alemania | |
| dc.description.fil | Fil: Toffalori, Cristina. Istituto di Ricovero e Cura a Carattere Scientifico; Italia | |
| dc.description.fil | Fil: Punta, Marco. Istituto di Ricovero e Cura a Carattere Scientifico; Italia | |
| dc.description.fil | Fil: Unger, Susanne. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: Burk, Ann Cathrin. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania | |
| dc.description.fil | Fil: Wehr, Claudia. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Maas Bauer, Kristina. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Melchinger, Wolfgang. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Haring, Eileen. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania | |
| dc.description.fil | Fil: Höfflin, Rouven. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Shoumariyeh, Khalid. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Hupfer, Valerie. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Lauer, Eliza Maria. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Duquesne, Sandra. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Lowinus, Theresa. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Núñez, Nicolás. Universitat Zurich; Suiza. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina | |
| dc.description.fil | Fil: Alberti, Chiara. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: da Costa Pereira, Sara. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: Merten, Carla Helena. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: Power, Laura. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: Weiss, Matthias. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Böke, Caroline. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Pfeifer, Dietmar. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Marks, Reinhard. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Bertz, Hartmut. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Wäsch, Ralph. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Ihorst, Gabriele. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Gentner, Bernhard. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Universite de Lausanne; Suiza | |
| dc.description.fil | Fil: Duyster, Justus. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Boerries, Melanie. German Cancer Research Center; Alemania. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Andrieux, Geoffroy. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Finke, Juergen. Universite de Fribourg (unifr); | |
| dc.description.fil | Fil: Becher, Burkhard. Universitat Zurich; Suiza | |
| dc.description.fil | Fil: Vago, Luca. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Vita Salute Universidad San Raffaele; Italia | |
| dc.description.fil | Fil: Zeiser, Robert. German Cancer Research Center; Alemania. Universite de Fribourg (unifr); | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Apostolova, Petya; Kreutmair, Stefanie; Toffalori, Cristina; Punta, Marco; Unger, Susanne; et al.; Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 203; 2; 10-2023; 264-281 | es |
| dc.identifier.eissn | 1365-2141 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/241849 | |
| dc.journal.ciudad | Londres | es |
| dc.journal.number | 2 | es |
| dc.journal.pagination | 264-281 | es |
| dc.journal.pais | Reino Unido | es |
| dc.journal.title | British Journal of Haematology | es |
| dc.journal.volume | 203 | es |
| dc.language.iso | eng | es |
| dc.publisher | Wiley Blackwell Publishing, Inc | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1111/bjh.19007 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/bjh.19007 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | AML | es |
| dc.subject | HCT | es |
| dc.subject | HMA | es |
| dc.subject.classification | Inmunología | es |
| dc.subject.classification | Medicina Básica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.72ebb66a-3564-49a4-b826-2d5f84192eb3_B.pdf
- Tamaño:
- 14.99 MB
- Formato:
- Adobe Portable Document Format